2023 Impact Factor Collection
Endocrine-Related Cancer has secured a Journal Impact FactorTM of over 4, after achieving a 2023 figure of 4.1 in the latest Journal Citation ReportsTM. It is now ranked 49 of 186 journals in the ‘Endocrinology & Metabolism’ category, rising to the 73rd percentile.
Explore the following top-cited research and reviews that contributed to our 2023 Journal Impact FactorTM.
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Andreas Venizelos et al.
The tumor microenvironment and immune responses in prostate cancer patients
J T W Kwon, R J Bryant, and E E Parkes
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms
James C Yao et al.
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?
Isabel Mayayo-Peralta, Wilbert Zwart, and Stefan Prekovic
Therapy considerations in neuroendocrine prostate cancer: what next?
Himisha Beltran and Francesca Demichelis
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer
Nicholas Mitsiades and Salma Kaochar
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review
Mirela Diana Ilie et al.
The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues
Garcilaso Riesco-Eizaguirre, Pilar Santisteban, and Antonio De la Vieja
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer
James F H Pittaway et al.
Redifferentiation-facilitated radioiodine therapy in thyroid cancer
Livia Lamartina et al.
